IA
TEVA icon

IFP Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

IFP Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.87M Buy
143,876
+1,532
+1% +$51K 0.09% 257
2026
Q1 		$4.29M Buy
142,344
+4,073
+3% +$131K 0.09% 249
2025
Q4 		$4.32M Buy
138,271
+137,580
+19,910% +$3.39M 0.1% 223
2025
Q3 		$14K Sell
691
-15
-2% -$263 ﹤0.01% 2749
2025
Q2 		$11.8K Buy
706
+15
+2% +$242 ﹤0.01% 2823
2025
Q1 		$10.6K Sell
691
-3,308
-83% -$59.1K ﹤0.01% 2559
2024
Q4 		$88.1K Buy
3,999
+1,960
+96% +$35.7K ﹤0.01% 1532
2024
Q3 		$36.7K Buy
2,039
+1,898
+1,346% +$33.2K ﹤0.01% 1873
2024
Q2 		$2.29K Hold
141
– – ﹤0.01% 2783
2024
Q1 		$1.99K Hold
141
– – ﹤0.01% 2694
2023
Q4 		$1.47K Sell
141
-1,000
-88% -$9.34K ﹤0.01% 2749
2023
Q3 		$11.6K Sell
1,141
-707
-38% -$6.58K ﹤0.01% 2193
2023
Q2 		$13.9K Buy
1,848
+611
+49% +$4.95K ﹤0.01% 2178
2023
Q1 		$39.7K Buy
1,237
+368
+42% +$3.64K ﹤0.01% 1689
2022
Q4 		$28K Sell
869
-631
-42% -$5.51K ﹤0.01% 2654
2022
Q3 		$47K Buy
1,500
+291
+24% +$2.57K ﹤0.01% 2420
2022
Q2 		$38K Hold
1,209
– – ﹤0.01% 2363
2022
Q1 		$38K Buy
1,209
+212
+21% +$1.77K ﹤0.01% 2363
2021
Q4 		$10K Sell
997
-32,820
-97% -$296K ﹤0.01% 2243
2021
Q3 		$333K Sell
33,817
-15,305
-31% -$143K 0.01% 725
2021
Q2 		$482K Buy
49,122
+13,415
+38% +$142K 0.01% 560
2021
Q1 		$411K Buy
35,707
+7,000
+24% +$80.3K 0.01% 581
2020
Q4 		$278K Buy
28,707
+27,806
+3,086% +$266K 0.01% 691
2020
Q3 		$8K Sell
901
-1,020
-53% -$10.8K ﹤0.01% 2004
2020
Q2 		$23K Sell
1,921
-26,825
-93% -$303K ﹤0.01% 1519
2020
Q1 		$230K Buy
28,746
+28,145
+4,683% +$288K 0.02% 531
2019
Q4 		$5K Sell
601
-15
-2% -$134 ﹤0.01% 2197
2019
Q3 		$3K Buy
+616
New +$4.72K ﹤0.01% 2580
2019
Q1 		$2K Sell
130
-3,976
-97% -$70.1K ﹤0.01% 2117
2018
Q4 		$64K Sell
4,106
-2,916
-42% -$59.8K ﹤0.01% 1457
2018
Q3 		$151K Sell
7,022
-3,237
-32% -$75.2K 0.01% 1239
2018
Q2 		$249K Sell
10,259
-529
-5% -$10.8K 0.01% 955
2018
Q1 		$204K Hold
10,788
– – 0.01% 985
2017
Q4 		$204K Sell
10,788
-2,959
-22% -$44.5K 0.01% 988
2017
Q3 		$242K Buy
13,747
+1,118
+9% +$25.2K 0.01% 1027
2017
Q2 		$420K Buy
12,629
+459
+4% +$14.2K 0.02% 744
2017
Q1 		$391K Sell
12,170
-1,379
-10% -$47.1K 0.02% 793
2016
Q4 		$491K Buy
13,549
+5,004
+59% +$200K 0.02% 624
2016
Q3 		$393K Sell
8,545
-254
-3% -$13.3K 0.02% 669
2016
Q2 		$442K Buy
8,799
+8,669
+6,668% +$462K 0.02% 593
2016
Q1 		$2K Sell
130
-6,129
-98% -$360K ﹤0.01% 2114
2015
Q4 		$411K Buy
+6,259
New +$387K 0.03% 548

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

IFP Advisors's TEVA Position: Q2 2026 in Review

IFP Advisors increased its Teva Pharmaceuticals (TEVA) stake by 1.1% in Q2 2026, buying an estimated $51K and bringing the position to 143,876 shares worth $4.87M. The position accounts for 0.09% of the portfolio, ranked #257.

IFP Advisors first reported a position in TEVA in Q4 2015 and has held it in 42 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • IFP Advisors held 143,876 shares of Teva Pharmaceuticals worth $4.87M as of Q2 2026.
  • IFP Advisors bought 1,532 Teva Pharmaceuticals shares in Q2 2026, an estimated $51K.
  • Teva Pharmaceuticals made up 0.09% of IFP Advisors's portfolio in Q2 2026, its #257 holding.
  • IFP Advisors first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.